Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the role of 5-alpha-reductase inhibitors in prostate cancer prevention and highlights a medical quandary, but it reports no new clinical findings.

This review highlights that sexual dysfunction associated with 5-alpha-reductase inhibitors is recognized in clinical literature, with erectile dysfunction being the most common adverse effect, followed by ejaculatory dysfunction and decreased libido.

This study generated a pharmacophoric model for both isoforms of steroidal 5α-reductase using 6-azasteroids, providing a structural framework for designing new inhibitors.

This study found that a novel saw palmetto supercritical CO2 extract effectively inhibits 5α-reductase type II in vitro, suggesting its potential for promoting prostate health in benign prostatic hyperplasia.

In this study of male patients with 46,XY 5α-reductase type 2 deficiency, DHT therapy was effective in achieving penile enlargement during infancy, while testosterone replacement therapy proved more beneficial during puberty, possibly due to increased conversion to DHT.

This article reviews treatment-induced sexual dysfunctions related to 5-alpha-reductase inhibitors and reports no new results; it highlights the need to better define and understand this controversial topic.

This study found that among men with Benign Prostatic Hyperplasia, treatment with the 5α-reductase inhibitor finasteride for three months significantly reduced levels of dihydrotestosterone and estradiol, hormones involved in prostate enlargement, without altering follicle-stimulating hormone or luteinizing hormone levels.

In this review, 5α-reductase inhibitors like finasteride and dutasteride were found to significantly reduce prostate volume and stabilize hair loss, but they also carry risks of sexual dysfunction, necessitating careful patient evaluation and monitoring.

In this study, in silico screening and molecular simulations identified β-sitosterol and brassicasterol as stable potential inhibitors of 5α-reductase1, suggesting they could be explored for androgenic alopecia treatment.

This study identified novel selective androgen receptor modulators with enhanced in vivo pharmacological activity through structure-activity relationship analysis in castrated rats.

This study developed solid lipid nanoparticles for effective delivery of shRNA-encoding plasmids, showing reduced 5α-reductase levels in DU-145 cells without significant cytotoxicity.

This chapter discusses androgen receptors and protein synthesis in the prostate, reporting that DHT-dependent receptor protein translocation increases protein-synthesizing activity after androgen injection in rat models.

This review discusses the role of androgens in male sexual differentiation and characteristics and reports no new clinical results; it emphasizes the androgen dependence of male pattern scalp hair loss.

This study found that distinct isoenzymes of 3 beta-hydroxysteroid dehydrogenase are expressed in human adrenals and gonads compared to the placenta and skin.

This study found that inhibiting 5αR1 with dutasteride leads to peripheral insulin resistance and increased body fat in men, which may have implications for its use in treating benign prostatic hyperplasia.

This study examined the dementia risk in patients with benign prostatic hyperplasia using alpha-blockers and 5-alpha reductase inhibitors, finding no significant association between these medications and increased dementia risk compared to no treatment, but noted higher risk probabilities for certain 5ARIs.

In this study using a rat model, discontinuing dutasteride improved some relaxant responses but did not fully restore erectile function, indicating a potential time-dependent detriment of the drug.

This review reported that 5-alpha-reductase inhibitors were effective in stabilizing disease progression or reducing the rate of progression in some cases of frontal fibrosing alopecia, though evidence on safety remains limited.

This study uses cryo-electron microscopy to reveal how androgen receptor forms a non-obligate dimer to bind DNA, with implications for prostate cancer development.

This study identified a mutation in the steroid-binding domain of the androgen receptor gene associated with complete androgen insensitivity syndrome, impairing male sexual development due to altered androgen receptor protein function.

In this study, fraction No. 3 of Oryza sativa bran extract demonstrated high unsaturated fatty acid content and significant 5α-reductase inhibition, suggesting potential for developing anti-androgenic alopecia products.

This review discusses the role of dihydrotestosterone in benign prostatic hyperplasia and reports no new results; the authors highlight 5alpha-reductase inhibitors as a well-established treatment option.

This review found that 5α-reductase inhibitors are associated with slightly increased rates of sexual dysfunction, gynecomastia, and mood disorders, but the true significance and persistence of these effects remain unclear.

This review discusses the effects of 5ARI drugs on male reproductive parameters, reporting potential decreases in sperm count and motility more significantly in men with pre-existing oligozoospermia, but does not provide fertility outcomes.

In this retrospective, population-based cohort study, researchers found no significant difference in age-related macular degeneration incidence between BPH patients using 5α-reductase inhibitors and those on tamsulosin, but observed a slight increased risk with dutasteride compared to finasteride.

This study suggests that androgen receptor signaling might regulate cellular behavior in bladder urothelial carcinoma, with decreased receptor and enzyme presence potentially linked to tumor progression.

In this study, finasteride reduced the severity of dopaminergic behavior manifestations in rats without causing extrapyramidal side effects, unlike other antidopaminergic agents.

This study found no significant increase in depression risk associated with taking five-alpha reductase inhibitors for benign prostatic hyperplasia or alopecia, although further studies are needed to confirm these findings.

This review discusses the clinical applications and adverse effects of 5-alpha reductase inhibitors for treating benign prostatic hyperplasia and androgenic alopecia, noting controversies around their implications for other diseases, without reporting new results.